Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
406 Leser
Artikel bewerten:
(2)

Eden Capital Invests in Phlebotomy Training Specialists

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Eden Capital, a New York-based private equity firm focused on technology, business services, and education, announced its recent acquisition of Phlebotomy Training Specialists (PTS), a leading phlebotomy professional training provider in the U.S. The partnership marks a milestone in PTS' evolution towards becoming a national leader in the healthcare training education space.

Since its inception in 1993, PTS has delivered comprehensive hands-on training to professionals who aspire to become phlebotomists and recognize the need for practical, real-world knowledge, taught by seasoned professionals. PTS' team of experienced instructors has successfully trained over 100,000 graduates, equipping them with the skills and confidence to excel in the workforce.

Eden Capital's expertise in partnering with professional training companies aligns with PTS' mission to empower individuals seeking to start or advance their careers in healthcare. Together, PTS and Eden Capital aim to scale the company's operations nationally, expand its educational offering, and work with corporate partners to address industry needs.

"We are thrilled to embark on this exciting journey with Eden," said Brian Treu, founder and CEO of PTS. "Eden Capital's experience and resources will support us through this transformative chapter in our growth. Eden's investment will enhance our ability to reach a broader audience, extend our product offering and expand our corporate partnerships to address industry needs."

"For decades we have known about the healthcare labor shortages, which have only deepened through the pandemic," said Dina Said Dwyer, Founder and Managing Partner at Eden Capital. "PTS, through its approximately 90 centers, is training the next generation of healthcare professionals. We are excited to work with Brian and his team at PTS on their mission to deliver best-in-class healthcare training nationwide."

Willkie Farr & Gallagher LLP and Hogan Marren Babbo & Rose, Ltd. (regulatory) acted as legal advisors to Eden Capital. Financing was provided by Byline Bank and Graycliff Partners. RSM provided financial and tax advisory services. Oliver Wyman conducted the commercial due diligence. GVC Advisory Services Ltd. acted as M&A advisor and Wilson Bradshaw LLP provided legal advice to PTS.

About Eden Capital

Eden Capital is a New York-based sector-focused private equity firm backing leading management teams in technology, business services, and education companies. Eden partners with management teams, owners, founders, and industry experts to invest in small and medium sized companies featuring proven, scalable business models, profitable operating histories, and sustainable competitive advantages.

For more information, visit our website at www.edencp.com.

About Phlebotomy Training Specialists

Phlebotomy Training Specialists (PTS) is a healthcare training and education company specializing in phlebotomy. With a focus on real-world knowledge and hands-on practice, PTS has trained over 100,000 graduates to become marketable phlebotomists. Through flexible scheduling and top-tier instructors, PTS offers state-of-the-art education to anyone seeking an empowering and meaningful career path in healthcare.

For more information, visit our website at www.phlebotomyusa.com.

Contact Information

Emilie Hunt
office manager
emilie@edencp.com
1215889000

SOURCE: Eden Capital

.

View source version on accesswire.com:
https://www.accesswire.com/781123/eden-capital-invests-in-phlebotomy-training-specialists

© 2023 ACCESS Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.